Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies.

Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies.

Inappropriate signaling through the epidermal growth factor receptor family (EGFR1/ERBB1, ERBB2/HER2, ERBB3/HER3, and ERBB4/HER4) of receptor tyrosine kinases leads to unregulated activation of multiple downstream signaling pathways that are linked to cancer formation and progression. In particular,...

Full description

Bibliographic Details
Main Authors: Jimson W D'Souza, Smitha Reddy, Lisa E Goldsmith, Irina Shchaveleva, James D Marks, Samuel Litwin, Matthew K Robinson
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4227695?pdf=render

Internet

http://europepmc.org/articles/PMC4227695?pdf=render

Similar Items